Logo image of CHRS

COHERUS BIOSCIENCES INC (CHRS) Stock Fundamental Analysis

NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD

0.7561  -0.02 (-2.45%)

After market: 0.78 +0.02 (+3.16%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CHRS. CHRS was compared to 561 industry peers in the Biotechnology industry. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative. CHRS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CHRS had negative earnings in the past year.
In the past year CHRS has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CHRS reported negative net income in multiple years.
CHRS had negative operating cash flow in 4 of the past 5 years.
CHRS Yearly Net Income VS EBIT VS OCF VS FCFCHRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of CHRS (6.36%) is better than 93.23% of its industry peers.
Industry RankSector Rank
ROA 6.36%
ROE N/A
ROIC N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRS Yearly ROA, ROE, ROICCHRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CHRS has a better Profit Margin (10.68%) than 93.40% of its industry peers.
In the last couple of years the Profit Margin of CHRS has declined.
With a decent Gross Margin value of 55.97%, CHRS is doing good in the industry, outperforming 77.54% of the companies in the same industry.
In the last couple of years the Gross Margin of CHRS has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 10.68%
GM 55.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
CHRS Yearly Profit, Operating, Gross MarginsCHRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRS has more shares outstanding
CHRS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CHRS has an improved debt to assets ratio.
CHRS Yearly Shares OutstandingCHRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CHRS Yearly Total Debt VS Total AssetsCHRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -4.69, we must say that CHRS is in the distress zone and has some risk of bankruptcy.
CHRS has a Altman-Z score (-4.69) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.69
ROIC/WACCN/A
WACC7.25%
CHRS Yearly LT Debt VS Equity VS FCFCHRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.21 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS has a worse Current ratio (1.21) than 85.74% of its industry peers.
A Quick Ratio of 0.96 indicates that CHRS may have some problems paying its short term obligations.
CHRS has a Quick ratio of 0.96. This is amonst the worse of the industry: CHRS underperforms 88.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.96
CHRS Yearly Current Assets VS Current LiabilitesCHRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.94% over the past year.
The earnings per share for CHRS have been decreasing by -27.39% on average. This is quite bad
CHRS shows a small growth in Revenue. In the last year, the Revenue has grown by 3.78%.
The Revenue has been decreasing by -5.60% on average over the past years.
EPS 1Y (TTM)50.94%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-9.37%
Revenue 1Y (TTM)3.78%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-90.14%

3.2 Future

CHRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.71% yearly.
CHRS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.33% yearly.
EPS Next Y-38.38%
EPS Next 2Y-0.49%
EPS Next 3Y5.49%
EPS Next 5Y5.71%
Revenue Next Year-68.55%
Revenue Next 2Y-38.62%
Revenue Next 3Y-25.91%
Revenue Next 5Y-1.33%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CHRS Yearly Revenue VS EstimatesCHRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CHRS Yearly EPS VS EstimatesCHRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CHRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRS Price Earnings VS Forward Price EarningsCHRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRS Per share dataCHRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y5.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CHRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COHERUS BIOSCIENCES INC

NASDAQ:CHRS (5/23/2025, 9:22:01 PM)

After market: 0.78 +0.02 (+3.16%)

0.7561

-0.02 (-2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners57.37%
Inst Owner Change-5.02%
Ins Owners1.23%
Ins Owner Change-0.26%
Market Cap87.65M
Analysts80
Price Target5.37 (610.22%)
Short Float %30.92%
Short Ratio17.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.13%
Min EPS beat(2)-108.91%
Max EPS beat(2)92.65%
EPS beat(4)2
Avg EPS beat(4)1.67%
Min EPS beat(4)-108.91%
Max EPS beat(4)92.65%
EPS beat(8)4
Avg EPS beat(8)-50.64%
EPS beat(12)6
Avg EPS beat(12)-42.96%
EPS beat(16)7
Avg EPS beat(16)-48.51%
Revenue beat(2)2
Avg Revenue beat(2)14.72%
Min Revenue beat(2)12.3%
Max Revenue beat(2)17.15%
Revenue beat(4)3
Avg Revenue beat(4)6.85%
Min Revenue beat(4)-5.85%
Max Revenue beat(4)17.15%
Revenue beat(8)4
Avg Revenue beat(8)-2.17%
Revenue beat(12)4
Avg Revenue beat(12)-5.95%
Revenue beat(16)4
Avg Revenue beat(16)-7.3%
PT rev (1m)-10.81%
PT rev (3m)-13.49%
EPS NQ rev (1m)15.13%
EPS NQ rev (3m)20.27%
EPS NY rev (1m)9.69%
EPS NY rev (3m)-128.65%
Revenue NQ rev (1m)3.73%
Revenue NQ rev (3m)11.55%
Revenue NY rev (1m)-20.4%
Revenue NY rev (3m)-62.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS2.3
BVpS-1.14
TBVpS-1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.36%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.68%
GM 55.97%
FCFM N/A
ROA(3y)-30.71%
ROA(5y)-23.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-15.79%
GM growth 3Y-12.08%
GM growth 5Y-10.08%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.96
Altman-Z -4.69
F-Score5
WACC7.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.94%
EPS 3YN/A
EPS 5Y-27.39%
EPS Q2Q%-9.37%
EPS Next Y-38.38%
EPS Next 2Y-0.49%
EPS Next 3Y5.49%
EPS Next 5Y5.71%
Revenue 1Y (TTM)3.78%
Revenue growth 3Y-6.5%
Revenue growth 5Y-5.6%
Sales Q2Q%-90.14%
Revenue Next Year-68.55%
Revenue Next 2Y-38.62%
Revenue Next 3Y-25.91%
Revenue Next 5Y-1.33%
EBIT growth 1Y52.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.96%
EBIT Next 3Y23.38%
EBIT Next 5Y19.16%
FCF growth 1Y88.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.31%
OCF growth 3YN/A
OCF growth 5YN/A